Ярина: Main Uses and Benefits

Ярина, which contains drospirenone and ethinyl estradiol, is intended for use by females of reproductive potential for several key therapeutic domains.

Quick Facts

• Prevents pregnancy
• Treats symptoms of Premenstrual Dysphoric Disorder (PMDD)
• Manages moderate acne vulgaris

Its primary use is for pregnancy prevention. When taken as directed, the medication acts to prevent ovulation, supporting its role as a method of contraception.

Additionally, this drug is indicated for the treatment of symptoms associated with Premenstrual Dysphoric Disorder (PMDD). PMDD is a severe form of premenstrual syndrome characterized by emotional and physical symptoms that may cause considerable disruption. The medication is specifically for females who have chosen to use an oral contraceptive for birth control. Similarly, it is indicated for the management of moderate acne vulgaris in women who have achieved menarche and desire an oral contraceptive as their birth control method.

Patients should refer to the official prescribing information for a comprehensive list of indications and safety considerations.

The eligibility for using Ярина (Drospirenone and Ethinyl Estradiol) is strictly defined by regulatory bodies based on a patient's health history and specific risk factors. The official labeling specifies groups for whom the medicine is allowed, contraindicated, or restricted.

Eligibility Scope

Classification	Population/Condition	Regulatory Status
Allowed	Females of reproductive potential	General Eligibility
	Females ge 14 years who achieved menarche (for acne)	Age Threshold
Contraindicated	Women over 35 years of age who smoke	Absolute Exclusion
	History of thrombotic diseases (e.g., DVT, stroke, MI)	Absolute Exclusion
	Renal impairment or Adrenal insufficiency	Absolute Exclusion
	Liver tumors or active hepatic impairment	Absolute Exclusion
	Uncontrolled hypertension	Absolute Exclusion

Eligibility-Related Restrictions

Use is not recommended for women who are breastfeeding and is contraindicated if pregnancy occurs. For patients undergoing major surgery, regulatory labeling requires the medicine to be discontinued at least four weeks prior to the procedure and through two weeks after, due to vascular risk. The medicine is not indicated for use in the geriatric population or pre-menarchal females.

Interactions with other medicines and products

The interaction profile for Ярина (Drospirenone and Ethinyl Estradiol) is defined by pharmacokinetic changes and a specific pharmacodynamic risk, as officially documented in regulatory information.

Contraindicated Combinations

Co-administration with certain combination products for Hepatitis C is strictly prohibited. This restriction applies to medicines containing ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, due to the officially documented risk of significant Alanine Transaminase (ALT) elevations.

Pharmacokinetic and Metabolic Interactions

Substances that alter the body’s metabolism of the hormones may compromise efficacy or increase exposure:

• Enzyme Inducers: Medicines or herbal products that induce metabolic enzymes (e.g., CYP3A4), such as certain anticonvulsants (phenytoin, carbamazepine) or St. John’s Wort, cause a pharmacokinetic interaction that reduces the plasma concentrations of the hormones.
• Enzyme Inhibitors: Strong inhibitors of CYP3A4, such as Ketoconazole, cause a pharmacokinetic interaction that increases the systemic exposure (AUC) of drospirenone.

Pharmacodynamic and Hyperkalemia Risk

The progestin component, drospirenone, has antimineralocorticoid activity, creating an additive pharmacodynamic risk of hyperkalemia (elevated potassium) when combined with other drugs that increase serum potassium. These interacting drug categories include ACE inhibitors, Angiotensin II Receptor Blockers (ARBs), potassium-sparing diuretics, and NSAIDs when used chronically. This hyperkalemia risk is a specific population consideration, as it is heightened in patients with documented renal impairment.

Ярина, a combination of ethinyl estradiol (EE, an estrogen component) and drospirenone (DRSP, a progestin component), functions via a multi-faceted pharmacodynamic mechanism.

EE and DRSP exert a negative feedback effect on the hypothalamic-pituitary-ovarian axis. This interaction suppresses the release of Gonadotropin-Releasing Hormone (GnRH) from the hypothalamus, subsequently reducing the pituitary secretion of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH). This downstream cascade inhibits follicular development in the ovaries, preventing the LH surge required for ovulation.

Simultaneously, the DRSP component acts as an agonist at the progesterone receptor (PR) and a competitive antagonist at the mineralocorticoid receptor (MR) and androgen receptor (AR). PR activation alters the endometrial lining and increases the viscosity of cervical mucus, physically impeding sperm transport. MR antagonism blocks the action of aldosterone, inhibiting sodium and water reabsorption in the distal renal tubules, modulating systemic fluid dynamics. AR antagonism reduces the downstream effects of circulating androgens.

The medicine Drospirenone and Ethinyl Estradiol is administered via the oral route as a fixed-dose tablet. The official dosing regimen requires the administration of one tablet daily for 28 consecutive days, a structured schedule intended for long-term use for its approved indications. The daily dose may be taken with or without food but is consistently advised to be taken at the same time every day to maintain the intended hormonal level throughout the cycle.

The administration follows a precise, sequential cyclic pattern. The typical 28-day regimen consists of a set number of active (hormone-containing) tablets followed immediately by inert (hormone-free) tablets. Strict adherence to the sequential order of tablets, as directed on the blister pack, is a fundamental procedural condition of use. The entire 28-day sequence must be completed, and the next cycle must begin immediately the day after the last tablet of the previous pack, without interruption.

Usage is restricted to females of reproductive potential who have achieved menarche. For the specific use in managing moderate acne, the regimen is officially indicated for females at least 14 years of age. A crucial special procedural condition for the initial cycle mandates the use of a non-hormonal barrier method for the first seven consecutive days to ensure adequate coverage during the establishment of the hormonal regimen. Failure to follow the ordered intake or an incident that compromises absorption, such as severe vomiting within 3–4 hours of dosing, requires adherence to specific missed-dose rules outlined in the official labeling.

Research Evidence / Overview of Studies for Ярина (Drospirenone/Ethinyl Estradiol)

This overview describes the types of official research that have been conducted for this medication, focusing on the study designs, the populations examined, and what remains unclear in the evidence landscape. This information should be used for context and does not provide clinical or usage advice.

---

Evidence for Use in Pregnancy Prevention (Contraception)

The research base for contraceptive use was built primarily upon large-scale clinical trials and long-running observational studies. These studies included women of reproductive age who used this medication for the purpose of contraception. Researchers monitored the occurrence of pregnancy over defined periods to assess the overall outcome.

The main measure used in these studies is the Pearl Index, which researchers report describes the number of pregnancies observed per 100 woman-years of exposure to the drug. Findings describe patterns observed in these studies regarding pregnancy rates, an outcome measured when the drug was taken as directed. Researchers also examined cycle control, monitoring the patterns and regularity of bleeding over many treatment cycles.

What remains unclear is the consistency of the findings in the day-to-day, real-world setting, where the overall outcome may be influenced by patient adherence (or compliance) to the daily regimen. The bulk of the long-term data also comes from large observational studies rather than head-to-head randomized trials. Comparative evidence is lacking for many older Combined Oral Contraceptives (COCs).

---

Evidence for Use in Premenstrual Dysphoric Disorder (PMDD)

The evidence for the use of this drug for the studied PMDD symptoms is primarily derived from randomized, double-blind, placebo-controlled trials (RCTs). These trials were designed to observe symptom patterns in groups receiving the study drug versus groups receiving an inactive placebo pill. These trials focused on women who met the clinical criteria for PMDD and were also using an oral contraceptive.

Researchers examined patient-reported outcomes describing perceived discomfort, specifically measuring changes in both emotional and physical symptoms using validated scales, such as the Daily Record of Severity of Problems (DRSP). Studies also monitored outcomes reflecting daily functioning or activity level, such as the impact of symptoms on productivity and social relationships. Findings describe patterns observed in the studies over the course of the treatment cycles. Some trials reported that symptom scores on scales like the DRSP differed between the group receiving the study drug and the group receiving the placebo at the end of the assessment period.

A key consideration in this research is the observation of a placebo effect, where women receiving the inactive pill also reported changes in their symptoms during the trials. Furthermore, the primary research exploring short-term symptom changes typically observed responses over three menstrual cycles. Therefore, there is limited information for long-term outcomes, and it is not established whether the reported symptom patterns persist beyond these initial three cycles. Additionally, this combination was not evaluated in clinical trials for less severe Premenstrual Syndrome (PMS).

---

Evidence for Use in Moderate Acne Vulgaris

The research for this indication was primarily conducted in randomized, controlled trials comparing the drug against a placebo. These studies included post-menarcheal women and adolescents (age 14 and older) who had a diagnosis of moderate acne vulgaris and were also using oral contraception.

Researchers monitored outcomes linked to inflammatory or irritative states, focusing on changes in both inflammatory lesions (e.g., pimples) and non-inflammatory lesions (e.g., blackheads and whiteheads) on the face. They also used global assessment scales where investigators rated the overall acne severity. The majority of these studies monitored responses over defined time intervals, typically up to six menstrual cycles (about six months). The studies describe the measured status of symptoms in the observed populations during this period.

The results apply only to the populations studied—specifically women with moderate acne who are also using the product for birth control. Data for certain groups remain insufficient, as the trials did not extensively study women with mild or severe forms of acne. Also, there is limited information for long-term outcomes, and research does not determine how the skin condition may change after stopping the medication.

---

Long-Term Study Durations and Follow-up

The duration of research follow-up varies by indication. Contraception is studied over extended observational periods and 1-year clinical trials. However, the evidence for PMDD symptoms and acne severity is based on shorter trials: typically three cycles for PMDD and six cycles for acne. This means that while research provides insight into short-term changes, long-term effects are not fully established for the PMDD and acne indications. Evidence contributes to understanding symptom patterns over these specific, limited time intervals but does not fully characterize the response durability over multiple years of continuous use.

---

Evidence in Special Populations and Subgroups

Research has explored the drug in certain groups, such as adolescents with moderate acne who are post-menarche. The evidence base also includes some studies examining the drug's measured responses in women of different ethnic backgrounds, where research describes similarity in observed patterns. However, comparative evidence is lacking in many other potential subgroups, and the data for certain groups remain insufficient. For instance, the drug was not evaluated in clinical trials for the treatment of less severe PMS.

---

What is Still Uncertain About the Research Evidence

A reported finding across the symptom-based trials (PMDD and acne) was the observation of a placebo effect, which makes it challenging to interpret the specific contribution of the medication with absolute certainty. Additionally, follow-up durations were limited in the acne and PMDD trials, meaning that data for long-term outcomes and the duration of any reported patterns remain unclear. Research provides context but not individual predictions, as study results reflect the specific conditions under which they were conducted. More comparative evidence is lacking between this specific oral contraceptive and many older, established options for some non-contraceptive uses.

Common questions about Ярина (FAQ)

---

Q: How quickly does the pill start working?

Official product information advises that if you start taking the pill later than the first day of your menstrual cycle, you must use an additional non-hormonal contraceptive method for the initial 7 consecutive days. This step is included in the instructions to help ensure the intended level of pregnancy prevention is established during the initial cycle.

Q: Is there an age limit for when I should stop using it?

Regulatory documents state that the pill is contraindicated (should not be used) for women over age 35 who smoke due to a high risk of serious cardiovascular events. For non-smoking women over 35 without other risk factors, the official advice highlights the necessity of assessing individual risk factors for blood clots.

Q: How soon after a miscarriage or abortion can I start taking the pill?

According to official product labeling, following a first-trimester abortion or miscarriage, the pill is stated as being an option for immediate start. Following a second-trimester abortion or miscarriage, the labeling indicates the pill is typically started between 21 and 28 days later.

Q: Is this safe for women who have never had a child (nulliparous)?

The pill is indicated for use by females of reproductive potential to prevent pregnancy. Regulatory documents define the population without specifying if the patient has previously given birth.

Q: What is the 'Black Box Warning' about?

The highest-level regulatory warning, known as the Boxed Warning, emphasizes that cigarette smoking increases the risk of serious cardiovascular events from combined oral contraceptive use. This risk is greater with increased age and is most pronounced in women over 35 who smoke heavily.

Q: What is the risk for women over 35 who do not smoke?

Regulatory documents indicate that the increased risk of serious cardiovascular events is greatest for women over 35 who smoke. For non-smoking women over 35, the decision to use the pill is based on a careful assessment of other individual risk factors for thrombotic disease (blood clots).

Q: If I experience sudden leg pain or swelling, what should I do?

The pill increases the risk of blood clots. Signs of a serious blood clot (such as deep vein thrombosis) include sudden pain, swelling, or tenderness in the leg. Regulatory documents advise that if these symptoms occur, the patient should stop taking the pill and seek emergency medical attention.

Q: How long do initial side effects (e.g., nausea, breast tenderness) usually last?

Studies show that common adverse reactions include nausea and breast pain/tenderness. Also, irregular bleeding or spotting often occurs, especially during the first three months of use. However, the exact duration for an individual’s symptoms to resolve is not specified in regulatory information.

Q: Is hair loss a possible side effect?

According to official labeling, Alopecia (hair loss) has been reported during the postmarketing experience of the drug. Postmarketing experience includes reports gathered after a drug has been made available to the public.

Q: What is the likelihood of mood changes (like anxiety or depression) occurring?

In clinical trials for contraception, 'mood changes' were reported as an adverse reaction by a percentage of users (2.3%). Studies for its use in Premenstrual Dysphoric Disorder (PMDD) also reported symptoms like irritability and decreased libido in a small percentage of users.

Q: Can the pill affect my sex drive (libido)?

Official documents indicate that changes in libido (an increase or decrease in sex drive) have been reported in postmarketing experience. In clinical trials for PMDD, 'decreased libido' was reported by 2.8% of users.

Q: Can the pill cause eye changes, such as blurred vision or difficulty wearing contact lenses?

The product labeling warns that signs of a serious blood clot, such as sudden vision loss or a change in vision, require immediate medical attention. Also, contact lens wearers who develop vision changes or an inability to wear their lenses should consult an eye specialist.

Q: Are there any other skin changes (e.g., rashes, pigmentation) other than acne improvement?

The official label warns that the pill can cause chloasma, which is the darkening of skin, especially in women with a history of chloasma gravidarum (pregnancy-related skin darkening). Postmarketing reports also include other skin-related adverse reactions, such as urticaria (hives) and rash.

Q: If I stop taking the pill due to nausea, how long might the nausea last?

Nausea/vomiting was a frequent adverse reaction reported in clinical trials. However, the regulatory documents do not specify the exact time frame for these symptoms to resolve after an individual stops taking the drug.

Q: How long can a person safely stay on the pill, according to general medical knowledge?

The drug is intended for long-term use for its approved indications. The research for its contraceptive use includes extended observational periods. Regulatory documents do not define a maximum time frame for use but require continuous reassessment of risk factors.

Q: How common are light periods or missed periods (amenorrhea) while taking this?

Official information indicates that women taking this pill may experience very light or no periods, known as amenorrhea. If a period is missed and the tablets have been taken correctly, the likelihood of pregnancy is low. If two consecutive periods are missed, pregnancy should be ruled out.

Q: Has it been studied for any impact on long-term bone density?

Safety concerns were not identified in the clinical program for this pill. However, the FDA required a post-marketing study to evaluate the impact on bone mineral density for a related drospirenone-only product, as progestin-only contraceptives have been associated with bone loss.

Q: Does my body weight affect the pill's effectiveness?

The official product labeling for this combined oral contraceptive does not specify a difference in efficacy by body weight. Clinical studies for a related product also did not suggest a greater risk of pregnancy in a subgroup of patients with a higher Body Mass Index (BMI).

Q: What are the specific missed dose rules for the different colored pills?

Regulatory information provides specific instructions for missed active (hormone-containing) tablets, including when to take the tablet as soon as possible and when to use back-up contraception if two or more are missed in sequence. Inert (hormone-free) tablets have no hormonal consequence if missed.

Q: What is the difference between the active and placebo pills?

The colored tablets are the active pills and contain the synthetic hormones drospirenone and ethinyl estradiol. The white or off-white tablets are inert or placebo pills and do not contain any active hormonal ingredients.

Q: What key information should I tell my doctor before starting the pill?

Patients should inform their doctor of a history of blood clots, stroke, heart attack, uncontrolled high blood pressure, and severe headaches or migraines with certain symptoms. This also includes any history of kidney or adrenal insufficiency, or current or past hormone-sensitive malignancies like breast cancer.

Q: Does it affect the results of routine blood tests?

Official documents state that combined oral contraceptives (COCs) can influence the results of certain laboratory tests. These include tests for coagulation factors, lipids, and various binding proteins.

Q: Is this medication ever used as a hormone replacement therapy (HRT)?

Official documents classify this combination for contraception, acne, or PMDD indications, and it is not indicated for hormone replacement therapy (HRT).

Q: Can I eat grapefruit or drink grapefruit juice while taking it?

Official labeling warns that grapefruit or grapefruit juice may increase the blood levels of the drospirenone component by inhibiting certain metabolic enzymes (CYP3A4). This interaction could potentially increase the occurrence of side effects, such as elevated potassium (hyperkalemia).

Q: Do antibiotics always make this pill less effective?

Regulatory documents advise that some drugs, including certain antibiotics (such as Rifampicin), can significantly decrease the pill's effectiveness. Regulatory advice states that patients using such enzyme-inducing drugs should consider using a back-up or alternative method of contraception.

The storage and disposal of Ярина (drospirenone and ethinyl estradiol) must strictly adhere to the conditions documented in the official regulatory labeling.

Required Storage Conditions

• Temperature: The medicine must be stored at a temperature below 30 °C (86 °F).
• Protection: It is required to keep the product in its original package to ensure protection from light and moisture.
• Handling: The medicine must not be frozen.
• Child Safety: Keep this medicine out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Expired or unused Ярина must be handled according to strict pharmaceutical waste guidelines. The product must not be disposed of in household waste or wastewater (e.g., flushed down a toilet or poured down a sink). Disposal must be done in accordance with local requirements, often involving returning the medicine to a pharmacy or an official collection point.